Management of specific symptom complexes in patients receiving palliative care

CMAJ. Canadian Medical Association Journal

Volumn 158, Issue 13, 1998, Pages 1717-1726

  Bruera, Eduardo ^a,b   Neumann, Catherine M ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b GREY NUNS COMMUNITY HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CORTICOSTEROID; GESTAGEN; HALOPERIDOL; NEUROLEPTIC AGENT; OPIATE AGONIST;

CACHEXIA; CANCER PAIN; CANCER PALLIATIVE THERAPY; DELIRIUM; DYSPNEA; HUMAN; NAUSEA; NEUROTOXICITY; REVIEW; SLOW RELEASE FORMULATION;

EID: 0032581076     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Eve A, Smith AM, Tebbit P. Hospice and palliative care in the UK 1994/5, including a summary of trends 1990/5. Palliat Med 1997;11:31-43.
2. Ripamonti C, Bruera E. Pain and symptom management in palliative care. Cancer Control 1996;3(3):204-13.
3. Agency for Health Care Policy Research (AHCPR). Clinical practice guidelines for the management of cancer pain. AHCPR pub! no 94-0592. Rockville (MD): US Department of Health and Human Services; 1994.
4. Levy MH. Pharmacological treatment of cancer pain. N Engl J Med 1996;335(15):1124-32.
5. World Health Organization. Cancer pain relief. Geneva: The Organization; 1986.
6. Au H, Bruera E, MacDonald N. The assessment and management of cancer pain in a tertiary care Canadian teaching hospital [abstract 595]. Clin Invest Med 1995;18(4 Suppl):B90.
7. Bruera E, Brenneis C, Michaud M, MacDonald RN. Influence of the pain and symptom control team (PSCT) on the patterns of treatment of pain and other symptoms in a cancer center. J Pain Symptom Manage 1989;4(3):112-6.
8. Cleeland CS, Gonin R, Hatfield AK, Edmonson JH, Blum RH, Stewart JA, et al. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 1994;330(9):592-6.
9. Stiefel P, Morant R. Morphine intoxication during acute reversible renal insufficiency. J Palliat Care 1991;7(4):45-7.
10. Lane NE. Pain management in osteoarthritis: the role of COX-2 inhibitors. J Rheumatol 1997;24(Suppl 49):20-4.
11. Walsh TD, MacDonald N, Bruera E, Shepard KV, Michaud M, Zanes R. A controlled study of sustained-release morphine sulfate tablets in chronic pain from advanced cancer. Am J Clin Oncol 1992;15(3):268-72.
12. Bruera E, Sloan P, Mount B, Scott J, Suarez-Almazor M. A randomized, double-blind, double-dummy, crossover trial comparing the safety and efficacy of oral sustained-release hydromorphone with immediate-release hydromorphone in patients with cancer pain. Canadian Palliative Care Clinical Trials Group. J Clin Oncol 1996;14(5):1713-7.
13. Coluzzi P. A titration study of oral transmucosal fentanyl citrate for breakthrough pain in cancer patients [abstract 143]. Proc Am Soc Clin Oncol 1997;16:41a.
14. Ripamonti C, Bruera E. CNS adverse effects of opioids in cancer patients. Guidelines for treatment. Cent Nerv Syst Drugs 1997;8(1):21-37.
15. Bruera K, Pereira J. Neuropsychiatric toxicity of opioids. in: Jensen TS, Turner JA, Wiesenfeld-Hallen Z, editors. Proceedings of the 8th World Congress on Pain, Progress in Pain Research and Management. Vol 8. Seattle: international Association for the Study of Pain Press; 1997. p. 717-38.
16. Bruera E, Pereira J, Watanabe S, Belzile M, Kuehn N, Hanson J. Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone and morphine. Cancer 1996;78(4):852-7.
17. Lawlor PG, Turner KS, Hanson J, Bruera ED. Dose ratio between morphine and methadone in patients with cancer pain. Cancer 1998;82:1167-73.
18. DeWys WD, Begg C, Lavin PT, Band PR, Bennett JM, Bertino JR, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am J Med 1980;69:491-7.
19. Billingsley KG, Alexander HR. The pathophysiology of cachexia in advanced cancer and AIDS. In: Bruera E, Higginson I, editors. Cachexia-anorexia in cancer patients. Oxford: Oxford Medical Publications, Oxford University Press; 1996. p. 1-22.
20. Bruera E. ABC of palliative care: anorexia, cachexia and nutrition. BMJ 1997; 315:1219-22.
21. Klein S, Koretz RL. Nutrition support in patients with cancer: What do the data really show? Nutr Clin Pract 1994;9:91-100.
22. Fainsinger RL. Pharmacological approach to cancer anorexia and cachexia. In: Bruera E, Higginson I, editors. Cachexia-anorexia in cancer patients. Oxford: Oxford Medical Publications, Oxford University Press; 1996. p. 128-40.
23. Neuenschwander H, Bruera E. Asthenia. In: Doyle D, Hanks GWC, MacDonald N, editors. Oxford textbook of palliative medicine. 2nd ed. Oxford: Oxford University Press; 1998. p. 573-81.
24. Watanabe S, Bruera E. Corticosteroids as adjuvant analgesics. J Pain Symptom Manage 1994;9(7):442-5.
25. Beller E, Tattersall M, Lumley T, Levi J, Dalley D, Olver I, et al. Improved quality of life with megestrol acetate in patients with endocrine-insensitive advanced cancer: a randomised placebo-controlled trial. Ann Oncol 1997;8:277-83.
26. Bruera E, Ernst S, Hagen N, Spachynski K, Belzile M, Hanson J. Symptomatic effects of megestrol acetate (MA): a double-blind, crossover study [abstract 1716]. Proc. Am Soc Clin Oncol 1996;15:531.
27. Gagnon B, Bruera E. A review of the drug treatment of cachexia associated with cancer. Drugs 1998;55:675-88.
28. Pereira J, Bruera E. Chronic nausea. In: Bruera E, Higginson I, editors. Cachexia-anorexia in cancer patients. Oxford: Oxford Medical Publications, Oxford University Press; 1996. p. 23-37.
29. Bruera E, Seifert L, Watanabe S, Babul N, Darke A, Harsanyi Z, et al. Chronic nausea in advanced cancer patients: a retrospective assessment of a metoclopramide-based antiemetic regimen. J Pain Symptom Manage 1996;11(3):147-53.
30. Bruera E, MacEachern T, Spachynski K, LeGatt D, MacDonald RN, et al. Comparison of the efficacy, safety and pharmacokinetics of controlled release and immediate release metoclopramide for the management of chronic nausea in patients with advanced cancer. Cancer 1994;74(12):3204-11.
31. Mercadante S. The role of octreotide in palliative care. J Pain Symptom Manage 1993;9(6):406-11.
32. Neuenschwander H, Bruera E, Cavalli F. Matching the clinical function and symptom status with the expectations of patients with advanced cancer, their families, and health care workers. Support Care Cancer 1997;4:252-6.
33. Watanabe S, Bruera E. Anorexia and cachexia, asthenia and lethargy. Hematol Oncol Clin North Am 1996;10:189-206.
34. Breitbart W, Bruera E, Chochinov H, Lynch M. A National Cancer Institute of Canada Workshop on symptom control and supportive care in patients with advanced cancer: methodological and administrative issues. Neuropsychiatric syndromes and psychological symptoms in patients with advanced cancer. J Pain Symptom Manage 1995;10(2):131-41.
35. Bruera E, Miller L, McCallion J, Macmillan K, Krefting L, Hanson J. Cognitive failure in patients with terminal cancer: a prospective study. J Pain Symptom Manage 1992;7(4):192-5.
36. Pereira J, Hanson J, Bruera E. The frequency and clinical course of cognitive impairment in patients with terminal cancer. Cancer 1997;79(4):835-42.
37. Breitbart W, Marotta R, Platt MM, Weisman M, Derevenco M, Grau C, et al. A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatry 1996;153:231-7.
38. Bruera E, Ripamonti C. Dyspnea in patients with advanced cancer. In: Berger AM, Portenoy RK, Weissman DE, editors. Principles and practice of supportive oncology. Philadelphia: Lippincott-Raven Publishers; 1998. p. 295-308.
39. Bruera E, Schoeller T, MacEachern T. Symptomatic benefit of supplemental oxygen in hypoxemic patients with terminal cancer: the use of the N of 1 randomized controlled trial. J Pain Symptom Manage 1992;7(6):365-8.
40. Cohen MH, Anderson AJ, Krasnow SH, Spagnolo SV, Citron ML, Payne M, et al. Continuous intravenous infusion of morphine for severe dyspnea. South Med J 1991;84:229-34.
41. Bruera E, MacEachern T, Ripamonti C, Hanson J. Subcutaneous morphine for dyspnea in cancer patients. Ann Intern Med 1993;119(9):906-7.
42. Leung R, Hill P, Burdon J. Effect of inhaled morphine on the development of breathlessness during exercise in patients with chronic lung disease. Thorax 1996;51:596-600.
43. Davis C. The role of nebulised drugs in palliating respiratory symptoms of malignant disease. Eur J Palliat Care 1995;2:9-15.
44. Congleton J, Muers ME. The incidence of airflow obstruction in bronchial carcinoma, its relation to breathlessness, and response to bronchodilator therapy. Respir Med 1995;89:291-6.